Stay updated on Pembrolizumab in Pediatric Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Pediatric Solid Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Pediatric Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedAmendment 13 closed enrollment for rrCHL, MSI-H solid tumors, TMB-H solid tumors, and 12 to <18 years old with advanced melanoma, and Amendment 8 closed enrollment for solid tumors and melanoma in 6 months to <12 years old. These changes narrow participant eligibility and reflect updates to the study plan.SummaryDifference0.9%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page’s revision/version indicator has been updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check25 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check54 days agoChange DetectedEnrollment site update: Fargo, North Dakota (58102) was added as a current site, while the Fargo, North Dakota (58122) site was removed. The page revision has been updated to version 3.5.0.SummaryDifference0.2%

- Check68 days agoChange DetectedPage revision label updated from v3.4.2 to v3.4.3, indicating an internal update.SummaryDifference0.0%

- Check89 days agoChange DetectedRevision label on the page updated from v3.4.1 to v3.4.2, replacing the previous version.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in Pediatric Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Pediatric Solid Tumors Clinical Trial page.